Rational design and engineering of therapeutic proteins

Drug Discovery Today

Volumn 8, Issue 5, 2003, Pages 212-221

  Marshall, Shannon A ^a   Lazar, Greg A ^a   Chirino, Arthur J ^a   Desjarlais, John R ^a  

^a Xencor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALEMTUZUMAB; ASPARAGINASE MACROGOL; BASILIXIMAB; DACLIZUMAB; DENILEUKIN DIFTITOX; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INTERFERON BETA SERINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OKT 3; PALIVIZUMAB; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TRASTUZUMAB;

ACROMEGALY; ALLERGIC REACTION; ANEMIA; APLASIA; CANCER; CHEMICAL MODIFICATION; DIABETES MELLITUS; DRUG DESIGN; DRUG SOLUBILITY; DRUG STABILITY; GLYCOSYLATION; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKOPENIA; MULTIPLE SCLEROSIS; NONHUMAN; OLIGOMERIZATION; PROTEIN ENGINEERING; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTOPENIA;

ANIMALS; DRUG STABILITY; DRUG STORAGE; DRUG THERAPY; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037338175     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02610-2     Document Type: Review

References (67)

1. Pharmafocus (2002) Biotechnology 2006: Shaping the Future. Available at: http://www.pharmafile.com/Pharmafocus/Features/feature.asp?fID=281.
2. Voigt C.A., et al. Protein building blocks preserved by recombination. Nat. Struct. Biol. 9:2002;553-558.
3. Voigt C.A., et al. Computationally focusing the directed evolution of proteins. J. Cell. Biochem. Suppl. 37:2001;58-63.
4. Lin L. Betaseron. Dev. Biol. Stand. 96:1998;97-104.
5. Arakawa T., et al. Cysteine 17 of recombinant human granulocyte colony stimulating factor is partially solvent-exposed. J. Protein Chem. 12:1993;525-531.
6. Culajay J.F., et al. Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life. Biochemistry. 39:2000;7153-7158.
7. Desjarlais J.R., Handel T.M. De novo design of the hydrophobic cores of proteins. Protein Sci. 4:1995;2006-2018.
8. Hellinga H.W., Richards F.M. Optimal sequence selection in proteins of known structure by simulated evolution. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5803-5807.
9. Hurley J.H., et al. Design and structural analysis of alternative hydrophobic core packing arrangements in bacteriophage T4 lysozyme. J. Mol. Biol. 244:1992;1143-1159.
10. Dahiyat B.I., et al. Automated design of the surface positions of protein helices. Protein Sci. 6:1997;1333-1337.
11. Malakauskas S.M., Mayo S.L. Design, structure, and stability of a hyperthermophilic protein variant. Nat. Struct. Biol. 5:1998;470-475.
12. Marshall S.A., et al. Electrostatics significantly affect the stability of designed homeodomain variants. J. Mol. Biol. 316:2002;189-199.
13. Filikov A.V., et al. Computational stabilization of human growth hormone. Protein Sci. 11:2002;1452-1461.
14. Luo P., et al. Development of a cytokine analog with enhanced stability using computational ultrahigh throughput screening. Protein Sci. 11:2002;1218-1226.
15. Pipe S.W., Kaufman R.J. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc. Natl. Acad. Sci. U. S. A. 94:1997;11851-11856.
16. Agren L., et al. Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD. Protein Eng. 12:1999;173-178.
17. Tan P.H., et al. Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. Immunotechnology. 4:1998;107-114.
18. Sytkowski A.J., et al. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J. Biol. Chem. 274:1999;24773-24778.
19. Goldenberg M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin. Ther. 21:1999;75-87.
20. Syed S., et al. Potent antithrobmin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood. 89:1997;3243-3252.
21. Marques J.A., et al. A barbourin-albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. Thromb. Haemost. 86:2001;902-908.
22. Dennis M.S., et al. Albumin-binding as a general strategy of improving the pharmacokinetics of proteins. J. Biol. Chem. 277:2002;35035-35043.
23. Vajo Z., Duckworth W.C. Genetically engineered insulin analogs: diabetes in the new millenium. Pharmacol. Rev. 52:2000;1-9.
24. Knauf M.J., et al. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J. Biol. Chem. 263:1988;15064-15070.
25. Clark R., et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J. Biol. Chem. 271:1996;21969-21977.
26. Harris J.M., et al. Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40:2001;539-551.
27. Roberts M.J., et al. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54:2002;459-476.
28. Kinstler O., et al. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 54:2002;447-485.
29. Bailon P., et al. Rational design of a potent, long-lasting form of interferon: a 40-kDa-branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 12:2001;195-202.
30. Wang Y.S., et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54:2002;547-570.
31. MacDougall I.C., et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. 10:1999;2392-2395.
32. French A.R., et al. Intracellular traffiking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J. Biol. Chem. 270:1995;4334-4340.
33. Sarkar C.A., et al. Rational cytokine design for increased lifetime and enhanced potency using pH activated histidine-switching. Nat. Biotechnol. 20:2002;908-913.
34. Weintraub B.D., Szkudlinski M.W. Development and in vitro characterization of human recombinant thyrotropin. Thyroid. 9:1999;447-450.
35. Grossmann M., et al. A rational design strategy for protein hormone superagonists. Nat. Biotechnol. 16:1998;871-875.
36. Siemeister G., et al. An antagonistic vascular endothelial grown factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4625-4669.
37. Savino R., et al. Rational design of a receptor super-antagonist of human interleukin-6. EMBO J. 13:1994;5863-5870.
38. Fuh C., et al. Rational design of potent antagonists to the human growth hormone receptor. Science. 256:1992;1677-1680.
39. Olson, K. et al. (1998) Human Growth Hormone Variants. US patent number 5849535.
40. Lu C., et al. An isolated, surface expressed I domain of the integrin alphaL beta2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond. Proc. Natl. Acad. Sci. U. S. A. 98:2001;2387-2392.
41. Shimaoka M., et al. Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:2001;6009-6014.
42. Shimaoka M., et al. Computational design of an integrin I domain stabilized in the open high affinity conformation. Nat. Struct. Biol. 7:2000;674-678.
43. Antonelli G., Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur. Cytokine Netw. 10:1999;413-422.
44. He X.H., et al. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci. 65:1999;355-368.
45. Meyer D.L., et al. Reduced antibody response to streptavidin through site-directed mutagenesis. Protein Sci. 10:2001;491-503.
46. Laroche Y., et al. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood. 96:2000;1425-1432.
47. Worn A., Pluckthun A. Stability engineering of antibody single chain Fv fragments. J. Mol. Biol. 305:2001;989-1010.
48. Tamura M., et al. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J. Immunol. 164:2000;1432-1441.
49. Chen Y., et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 293:1999;865-881.
50. Rader C., et al. A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8910-8915.
51. Baca M., et al. Antibody humanization using monovalent phage display. J. Biol. Chem. 272:1997;10678-10684.
52. Griffiths A.D., Duncan A.R. Strategies for selection of antibodies by phage display. Curr. Opin. Biotechnol. 9:1998;102-108.
53. Maynard J., Georgiou G. Antibody engineering. Annu. Rev. Biomed. Eng. 2:2000;339-376.
54. Pluckthun A., Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology. 3:1997;83-105.
55. Ravetch J.V., Bolland S. IgG Fc receptors. Annu. Rev. Immunol. 19:2001;275-290.
56. Raghavan M., Bjorkman P.J. Fc receptors and their interactions with immunoglobulins. Annu. Rev. Cell Dev. Biol. 12:1996;181-220.
57. Shields R.L., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276:2001;6591-6604.
58. Shields R.L., et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277:2002;26733-26740.
59. Umana P., et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17:1999;176-180.
60. Ghetie V., et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol. 15:1997;637-640.
61. Kim J.K., et al. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn. Eur. J. Immunol. 29:1999;2819-2825.
62. Street A.G., Mayo S.L. Computational protein design. Structure Fold Des. 7:1999;R105-109.
63. Mendes J., et al. Energy estimation in protein design. Curr. Opin. Struct. Biol. 12:2002;441-446.
64. Pokala N., Handel T.M. Review: Protein design- Where we were, where we are, where we're going. J. Struct. Biol. 134:2001;269-281.
65. Kraemer-Pecore C.M., et al. Computational protein design. Curr. Opin. Chem. Biol. 5:2001;690-695.
66. Dahiyat B.I., Mayo S.L. Protein design automation. Protein Sci. 5:1996;895-903.
67. Dahiyat B.I., Mayo S.L. De novo protein design: fully automated sequence selection. Science. 278:1997;82-87.